Solventum to buy Acera Surgical for up to $850 million

Nov 20 (Reuters) - Medical device maker Solventum SOLV.N said on Thursday it would acquire privately held Acera Surgical for up to $850 million to expand its wound care portfolio.

Under the terms of the agreement, Solventum would pay $725 million in cash and additional up to $125 million contingent on the achievement of certain milestones. Shares of the Minnesota-based company were up nearly 5% in early trading.

The acquisition would bring Acera's Restrata, a synthetic treatment option for soft tissue repair, into Solventum's wound care portfolio.

Solventum is one of the largest providers of sterilization devices, wound dressings, medical tape and other hospital consumables used by healthcare facilities.

Restrata is made of non-woven fibers that slowly dissolve and is used to treat hard-to-heal, complex wounds. It stays in the wound long enough to act as a porous scaffold and aid in the healing process.

"Regenerative wound care is an exciting and fast-growing space, and Acera has innovative technology to meet a significant unmet need in acute wound care," Solventum CEO Bryan Hanson said.

Acera is expected to generate about $90 million in sales this year, Solventum said.

The company plans to use its cash on hand to finance the deal, which is expected to close in the first half of 2026.

Solventum expects the deal to be slightly dilutive to adjusted earnings per share in 2026, but accretive beginning in 2027.